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Abstract 
 
 
 
OBJECTIVES: We report our institutional experience and long-term results with the Sorin Freedom 
SOLO bovine pericardial stentless bioprosthesis.  
 
METHODS: Between January 2005 and November 2009, 149 patients (mean age 73.6±8.7 years, 68 
[45.6%] female) underwent isolated (n=75) or combined (n=74) aortic valve replacement (AVR) using 
the SOLO in our institution. Follow-up was 100% complete with an average follow-up time of 
5.9±2.6 years (maximum 9.6 years) and a total of 885.3 patient years.  
 
RESULTS: Operative (30-day) mortality was 2.7% (1.3% for isolated AVR [n=1] and 4.0% for 
combined procedures [n=3]). All causes of death were not valve-related. Preoperative peak (mean) 
gradients of 74.2±23.0 mmHg (48.6 ± 16.3 mmHg) decreased to 15.6±5.4 (8.8±3.0) after AVR, and 
remained low for up to 9 years. The postoperative effective orifice area (EOA) was 1.6 ±0.57 cm2, 
1.90±0.45 cm2, 2.12±0.48 cm2 and 2.20±0.66 cm2 for the valve sizes 21, 23, 25 and 27, respectively; 
with absence of severe prosthesis-patient-mismatch (PPM) and 0.7% (n=1) moderate PPM. During 
follow-up, Twenty-six patients experienced structural valve deterioration (SVD) and 14 patients 
underwent explantation. Kaplan-Meier estimates for freedom from death, explantation and SVD at 9 
years averaged 0.57 [0.47‒0.66], 0.82 [0.69‒0.90] and 0.70 [0.57‒0.79], respectively.  
 
CONCLUSIONS: The Freedom SOLO stentless aortic valve is safe to implant and shows excellent 
early and mid-term hemodynamic performance. However, SVD was observed in a substantial number 
of patients after only 5 ̶ 6 years and the need for explantation increased markedly, suggesting low 
durability.  
 
 
 
 
 
Ultramini abstract  
 
We report our institutional outcome in 149 patients receiving the Freedom SOLO bioprosthesis and up 
to 9.6 years of follow-up. The SOLO valve is safe to implant with excellent early hemodynamic 
performance. However, SVD and need for explantation increased markedly after only 5 ̶ 6 years, 
suggesting low durability.  
 
 
 
 
Keywords: aortic valve • stentless • bioprosthesis • cardiac surgery • valve surgery 
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Stentless bioprostheses were introduced as an attractive alternative to stented valves, combining the 1 
advantages of non-obstructive effective orifice area (EOA) and a flexible aortic root that was believed 2 
to be essential for natural leaflet stress distribution. Correspondingly, unstented xenografts, with 3 
minimal disruption of the aortic root anatomy and function, are expected to reduce dynamic stress on 4 
leaflets, and thereby limit valve degeneration and failure [1]. Whereas some earlier stentless porcine 5 
root prostheses showed unsatisfactory results with premature failure [2‒4], more advanced models 6 
were aimed at optimizing the tissue type, preservation and anticalcification treatments, as well as 7 
valve design. 8 
The third-generation bovine pericardium Freedom SOLO (henceforth SOLO) stentless bioprosthesis 9 
(Sorin Group, Saluggia, Italy) emerged as a modified version of the Pericarbon Freedom stentless 10 
valve in 2004 [5], and has recently received FDA approval for use in the US (June 24, 2014). The 11 
prosthesis is made of two bovine pericardial sheets for supra-annular subcoronary implantation using 12 
only one single suture line, thus reducing cross-clamp time. Furthermore, the SOLO is manufactured 13 
with a unique process that includes homocysteic acid (HCA) as an anticalcification treatment, to bind 14 
and neutralize free glutaraldehyde (GA) residues for optimal durability.  15 
Numerous reports have documented superior early and mid-term hemodynamic results for stentless 16 
valve prostheses, including the SOLO, in comparison to stented bioprostheses [6‒10]. Although the 17 
SOLO stentless valve has been used since 2004, no long-term outcome data (beyond mean 1.2 ± 0.8 18 
years) is available [10]. Thus, we are only now reaching an observation period that allows evaluation 19 
of  long-term outcome, particularly durability, which will eventually define non-inferiority compared 20 
to available alternative stented bioprostheses. As our institution introduced the SOLO stentless 21 
bioprosthesis at a particularly early stage, we report our operative results with the aim of assessing 22 
long-term clinical results, i.e. durability and freedom from major adverse events after up to 9.6 years 23 
of follow up. 24 
 25 
 26 
 27 
MATERIALS AND METHODS 28 
 29 
 30 
PATIENT POPULATION 31 
 32 
Between January 2005 and November 2009, 149 patients (mean age 73.6 ± 8.7 years, 68 [45.6%] 33 
female) underwent isolated (n=75) or combined (n=74) AVR using the SOLO bovine pericardial 34 
stentless valve bioprosthesis in our institution. The decision to use the SOLO stentless valve or an 35 
alternative, conventional stented prosthesis was at the surgeon’s discretion. The SOLO stentless valve 36 
was not considered suitable in cases with severe calcification of the aortic root, and in patients with 37 
true bicuspid valve and ectasia of the ascending aorta. The local ethics committee approved the review 38 
of patient data and patient consent was waived for the retrospective analysis. The patients’ 39 
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characteristics are shown in Table 1. One patient was operated with acute bacterial endocarditis 40 
(staphylococcus aureus), and four cases were re-do procedures. At the time of surgery, left ventricular 41 
ejection fractions (LVEF) ≤ 40% was present in 24 patients (16.1%).   42 
 43 
 44 
Surgical and postoperative management  45 
 46 
AVR procedures were all performed under routine general anesthesia and with a median sternotomy, 47 
using standard cardiopulmonary bypass and mild hypothermia (34°C). Cold blood cardioplegia was 48 
routinely used for myocardial protection. Aortotomy was performed approximately 1cm above the 49 
sinotubular junction (STJ). The diseased valve was then excised and the annulus carefully decalcified. 50 
The SOLO valve was implanted without rinsing in the supra-annular subcoronary position, with 3 51 
continuous suture lines using 4/0 prolene monofilament as reported in detail elsewhere [11]. In brief, 52 
sutures started at the base of each sinus, continued to the top of the commissures, and ended with 53 
extraaortic fixation. Transesophageal echocardiography (TEE) was routinely performed 54 
intraoperatively before and after AVR to assess the function of the prosthesis. No oral anticoagulation 55 
after hospital discharge was required in patients with the SOLO valve.  56 
 57 
 58 
Data collection, follow-up and definitions 59 
 60 
Perioperative data were retrieved from our prospectively managed institutional database (Dendrite 61 
Clinical Systems LTD, Henley-on-Thames, UK). Closing date for all follow-up investigations was Oct. 62 
1st, 2014. Follow-up was 100% complete with an average follow-up time of 5.9 ± 2.6 years (maximum 63 
9.6 years) and a total of 885.3 patient years. 64 
All patients were routinely examined with transthoracic echocardiography (TTE) before hospital 65 
discharge, at 6 months post-operatively and yearly thereafter. Intervals were shortened when changes 66 
or signs of degeneration were observed. Transvalvular pressure gradients and EOA were calculated 67 
using the modified Bernoulli equation and the continuity equation, respectively. Clinical status and 68 
adverse events were carefully assessed at each visit or by consultation with the referring physician. 69 
Dates of death were confirmed with data from local public authorities.  70 
Data analysis was performed as follows. Baseline characteristics and risk factors were defined 71 
according to EuroScore II criteria. Mortality and morbidity (rate of adverse events) were reported 72 
according to established guidelines [12, 13]. These guidelines define structural valve deterioration 73 
(SVD) as change in function or deterioration of an operated valve resulting from an intrinsic 74 
abnormality of the valve that causes stenosis or regurgitation, exclusive of infection or thrombosis. 75 
SVD includes wear, fracture, poppet escape, calcification, leaflet tear, stent creep, and suture line 76 
disruption of an operated valve [12, 13]. In absence of established reference values for prosthetic SVD, 77 
particularly for stentless valves, we defined intrinsic prosthetic stenosis, under normal flow conditions 78 
(EF>50%) and after normal postoperative function, when echocardiographic evidence of distinctive 79 
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and pronounced degenerative changes (such as severely impaired cusp movements due to thickened, 80 
sclerosed or calcified leaflets) was present (repeat measurements with different investigators) and at 81 
least two of the following criteria were met: (i) ≥ 3-fold increase of mean gradients compared to early 82 
postoperative measurements (before discharge) in (ii) ≥ 25 mmHg mean gradient; (iii) EOA of <1.5 83 
cm2 and iEOA < 0.9 cm2/m2 and peak velocity ≥3 m/sec or velocity time integral (VTI) of 0.5‒0.25 84 
(VTI was measured in the left ventricular outflow tract (LVOT) and the aortic valve (AoV) and 85 
expressed as LVOT/AoV). SVD due to regurgitation was defined as at least moderate regurgitation 86 
with pressure half time (PHT) ≤500ms and width of vena contracta (VC) ≥5 mm (if limited to one jet) 87 
or diastolic flow reversal in the descending or abdominal aorta in combination with echocardiographic 88 
evidence of abnormal prosthesis structure or motion. According to the generally accepted concept of 89 
prosthesis-patient-mismatch (PPM), the best variable for defining PPM is the ratio of prosthetic EOA 90 
to the patient’s body surface area (BSA) [14]. PPM mismatch was defined as an indexed EOA (iEOA) 91 
between 0.85 cm2/m2 and 0.65 cm2/m2 (moderate) and less than 0.65 cm2/m2 (severe), which are the 92 
established cut-off values for all types of prosthetic valves [14].  93 
 94 
 95 
Statistical analysis 96 
 97 
Demographic data are presented as mean values and standard deviation for continuous variables, and 98 
by number and percentages for categorical variables. Outcome data are presented as operative 99 
mortality, defined as death from any cause during or after surgery within 30 days if the patient was 100 
discharged, or within any interval if the patient was not discharged [12], or as Kaplan-Meier estimates 101 
of freedom from the following endpoints: death, SVD, explantation, thrombosis, endocarditis, or a 102 
combination of all. We used multivariate Cox proportional hazard ratio models to identify associations 103 
between patient- or procedure-related factors and endpoints. We used two linear mixed models, the 104 
first to analyze the effect of the valve replacement on the mean gradient, and the second to analyze the 105 
time effect on the mean gradient. Inspecting the residual plots with respect to the random and fixed 106 
effects, we detected outliers in the second model corresponding to those patients who developed SVD. 107 
As these patient provide particularly important information, we accepted the larger variance. All p-108 
values and confidence intervals are two-sided. All statistical analyses were performed using Stata 109 
(version 12, StataCorp, College Station, Texas USA). 110 
 111 
 112 
 113 
RESULTS 114 
 115 
 116 
Operative data, mortality and early complications 117 
 118 
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The mean extracorporeal circulation (ECC) and cross-clamp times were, respectively, 64 ± 14min (47 119 
± 13 min) and 95 ± 31 (71 ± 23 min) for isolated and combined procedures, with no significant 120 
differences among sizes 21, 23, 25 and 27. All patients left the operating room with no or trivial 121 
regurgitation.  122 
Overall operative (in-hospital) mortality was 2.7% (1.3% for isolated AVR [n=1] and 4.0% for 123 
combined procedures [n=3]). The corresponding EuroScore II overestimated the observed mortality 124 
considerably (Table 1). Causes of early death were not valve-related, i.e. low cardiac output and 125 
myocardial infarction (n=3) and embolism of the basilar artery (n=1) (Table 2). The four non-126 
surviving patients were older (77.9 ± 2.6 years vs. 73.4 ± 0.7 years, p=0.038) and had a significantly 127 
higher EuroScore II risk score (20.42 ± 20.74 vs. 5.29 ± 8.12, p<0.001) as compared to the 145 128 
surviving patients.  129 
In total, 25 patients experienced in-hospital complications (multiple complications possible), including 130 
temporary hemofiltration (HF) therapy for renal failure (of which four patients had renal impairment 131 
preoperatively). There were eight cerebral events, seven of which were fully reversible by the time of  132 
hospital discharge (three patients had previously suffered cerebral events). Five patients required 133 
drainage for pericardial or pleural effusions. There were two sternal re-explorations for impaired 134 
sternal healing. One permanent pacemaker was implanted due to complete AV-block. Including all 135 
patients with these early complications combined, the discharge from hospital occurred after a median 136 
length of stay (LOS) of 10.0 and 10.5 days for isolated and combined procedures, respectively. 137 
 138 
 139 
 140 
Hemodynamic and hematologic data  141 
 142 
The mean preoperative LVEF of 55.4 ± 12.3 improved to 58.6 ± 11.1, 61.5 ± 12.7, 61.7 ± 10.1, 62.4 ± 143 
10.1 and 63.0 ± 8.5 at 6 months, 1, 2, 3 and 4 years postoperatively (p<0.001). Preoperative peak 144 
gradients of 76.3 ± 25.3 mmHg decreased to 17.9 ± 9.8 mmHg postoperatively. Mean gradients 145 
decreased by -39.2 mmHg [p<0.001, 95% confidence interval from -42.4 to -35.9 mmHg] on average 146 
in every patient following AVR (Figure 1). Following the first postoperative measurement, the mean 147 
gradient increased by .94 mmHg [p<0.001, 95% confidence interval from .74 to 1.1] per year, but this 148 
was driven by 12 patients who reached a mean gradient >30 mmHg. Gradients showed a non-149 
significant trend for lower values with increasing valve size. The postoperative EOA (mean ± SD) for 150 
the valve sizes 21, 23, 25 and 27 were 1.67 ± 0.57 cm2, 1.90 ± 0.45 cm2, 2.12 ± 0.48 cm2 and 2.20 ± 151 
0.66 cm2, respectively. With the definition of PPM as the ratio of prosthetic EOA to the patient’s body 152 
surface area (BSA) and the use of established cut-off values [14], severe PPM was completely absent, 153 
and moderate PPM occurred in one patient (0.7%), however BMI was 37.7 and BSA was 2.02.  154 
Daily platelet counts were performed as part of the standard patient management protocol. Excluding 155 
patients with HF, infection and re-exploration, minimum platelet counts occurred following an 156 
average decrease of 59.9%. After reaching a nadir on the second postoperative day, platelet count 157 
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returned to baseline value, on average, on the 8th postoperative day. No excess or unexpected bleeding 158 
or re-exploration was associated with the SOLO valve.  159 
 160 
 161 
Long-term survival and freedom from major adverse events  162 
 163 
54 patients died during the follow-up period. The survival rate at 7, 8 and 9 years was 66%, 59% and 164 
57%, respectively (Table 3, Figure 2). Multivariate Cox regression analysis identified age (HR=1.06 165 
[1.02‒1.11], p=0.008) and renal dysfunction (HR=1.94 [1.02‒3.68], p=0.044) as parameters 166 
independently associated with survival, in contrast to arterial hypertension (HR=2.75 [0.85‒8.85], 167 
p=0.091), concomitant coronary artery bypass grafting (CABG) (HR=1.18 [0.70‒2.05], p=0.544), 168 
combined procedures (HR=1.12 [0.65‒1.93], p=0.680) and indexed PPM (EOA/BSA as continuous 169 
variable; HR=1.00 [0.73‒13.76], p=1.000).  170 
In 14 patients, the SOLO prostheses required explantation due to valve-independent dysfunction (n=5; 171 
i.e. thrombus formation, oversizing, aortic dilatation, endocarditis and suture dehiscence) or valve-172 
dependent failure (n=9). Of these, five SOLO required explantation due to severe functional stenosis 173 
and gross calcification that was always strikingly severe and included the entire aortic root. Four cases 174 
presented with acute regurgitation due to leaflet rupture, all of which were size 23 and 25 prostheses. 175 
In all these cases of non-sclerotic SVD, vertical tears were notably located in close proximity to the 176 
non-coronary/right-coronary commissure (NCC/RCC), and in our series they occurred, on average, 1.5 177 
years (6.0 vs. 7.5 years) earlier than explantation for degenerative stenosis. Two patients (14.3%) did 178 
not survive reoperation; one due to sudden cardiac arrest of unknown cause on the 8th postoperative 179 
day, and the second, because of right ventricular failure. 180 
There were 26 cases of SVD documented during the follow-up period (Figure 2, Table 3), of 181 
which only 10 underwent reoperation. The remaining 16 patients were not re-operated because of 182 
presumed excessive surgical risk, stable valve dysfunction or because the patient declined surgical 183 
treatment. Multivariate Cox regression analysis identified younger age (HR=0.93 [0.89‒0.97], 184 
p=0.002) as an independent predictor for SVD, but not renal dysfunction (HR=1.15 [0.26‒5.14], 185 
p=0.855), diabetes (HR=1.39 [0.54‒3.55], p=0.495), arterial hypertension (HR=2.60 [0.62‒10.80], 186 
p=0.189), nor PPM (EOA/BSA) as continuous variable (HR=0.10 [0.10‒7.26], p=0.855). 187 
Four patients experienced endocarditis, two of which underwent valve explantation and replacement, 188 
and the two other patients did not undergo re-operation and died 3 and 8 months after diagnosis, 189 
respectively. One patient presented with a large thrombotic adhesion on the NCC and underwent 190 
reoperation 5 months after the primary AVR.  191 
Combining all endpoints, 78 (52%) patients experienced an event. We included age, gender, isolated 192 
procedure, hypertension, indexed EOA, renal dysfunction, diabetes and EuroScore II in a Cox 193 
regression analysis with the combined endpoint; only EuroScore II showed an association (HR=1.02 194 
[0.02‒1.00], p=0.018), suggesting heterogeneous associations between independent variables and 195 
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individual endpoints, and indicating that no patient- or procedure-specific parameter alone permits 196 
prediction of prosthesis failure. 197 
 198 
 199 
 200 
COMMENT 201 
 202 
In the present study, we report our clinical results in a cohort of 149 patients with the longest follow-203 
up available to date for the third generation SOLO stentless bioprosthesis. Our data suggest that the 204 
valve is safe to implant, and provides an excellent early hemodynamic performance. However, 205 
freedom from SVD and explantation decreased markedly in our single center study after only 5‒6 206 
years, implying that the SOLO durability is considerably lower than that of conventional stented 207 
prostheses. 208 
The SOLO represents the most advanced stentless bioprosthesis that combines the single-suture, 209 
subcoronary implantation technique with the latest-generation bovine pericardial tissue and a novel 210 
anticalcification treatment. Consistent with previous reports [7‒10], we demonstrate excellent early 211 
results of the SOLO, relatively easy implantation with acceptable cross-clamp times, low gradients 212 
and large EOA, as well as near absence of PPM.  213 
As a unique SOLO-dependent side-effect, and consistent with previous reports [7, 8, 10, 15, 16], we 214 
observed postoperative thrombocytopenia following implantation, with a mean decrease of 59.9% in 215 
platelet numbers on the second postoperative day, followed by full recovery within 8 days. 216 
Importantly, and unexpectedly, SOLO-related excess bleeding complications, thromboemboli or 217 
increased re-exploration rates have not been observed despite this transient thrombocytopenia. 218 
Furthermore, there is no evidence for excess platelet activation, platelet consumption, or change in 219 
postoperative platelet function [17]. Causal hemodynamic flow-dependent mechanical damage 220 
appears highly unlikely given the large EOA and low gradients with correctly sized SOLO valves, 221 
with performances similar to native aortic valves at rest and under stress conditions [9, 18]. Contrary 222 
to observation, the platelet-damaging effect would be expected to persist if SOLO-related 223 
hemodynamic stress was causal. In agreement with the suggestion of a patient-independent effect 224 
derived from a study with propensity matched design [16], we hypothesize that a temporary, 225 
chemistry-induced lysis leads to lower platelet counts in patients with the SOLO, although the precise 226 
mechanism of thrombocytopenia remains to be identified. 227 
A number of stentless valve prostheses have been developed and introduced, but all have been 228 
fundamentally different with respect to design, tissue type and anticalcification treatment, rendering 229 
comparisons difficult. Concerns have been raised for stentless prostheses regarding long-term 230 
durability; most likely resulting from experiences with earlier (porcine root) models, for which, after 231 
approximately 10 years, freedom from SVD and reoperation dropped dramatically, e.g. the O`Brien 232 
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(CryoLife, Atlanta, GA) [2], Shelhigh (Shelhigh, Inc, Millburn, NJ) [3], Biocor [19] and Toronto SPV 233 
(both St. Jude Medical, St. Paul, MN) [4].  234 
In our single institution experience freedom from thromboembolism and endocarditis was high and 235 
comparable to that reported for other stentless and stented bioprosthesis [20‒24], but freedom from 236 
SVD and explantation in our series was much lower than expected. Freedom from explantation after 9 237 
years was only 0.82 in our cohort is, comparing to 0.97 and 0.98 reported for the conventional stented 238 
Hancock II (Medtronic Inc, Minneapolis, MN) [21, 22], and Perimount Magna (Edwards Lifesciences, 239 
Irvine, CA) [22, 23] bioprostheses at 10 years. Prostheses with tears and cusp ruptures in our series 240 
were relatively easy to replace; however, cases with severe calcification turned out to require very 241 
difficult and demanding re-operations. The freedom from SVD in our series was only 0.70 after 9 242 
years, substantially lower than rates of 0.86 to 0.97 reported for conventional stented valves at 10 243 
years, i.e. the Hancock II [21, 22], Mosaic (Medtronic Inc, Minneapolis, MN) [24], and Perimount 244 
Magna [22].  245 
The morphological and hemodynamic criteria defined in this study for SVD indicate intrinsic changes 246 
in the valve suggesting at least moderate aortic stenosis associated with left ventricular hypertrophy 247 
[26], substantial complications and event rates from AS [27], impaired event-free survival and 248 
increased overall mortality [28]. Thus the definition for SVD in our study is rather conservative 249 
considering the generally larger EOA and lower gradients of stentless vs. stented valves.  250 
 251 
In general, SVD is influenced by the tissue structure (e.g. bovine vs. porcine), the design of the valve, 252 
as well as its mechanical wear and stress absorption properties. Notably, chemical fixation and the 253 
anticalcification treatment are considered key elements in valve manufacturing aimed at enhancing 254 
valve durability, and avoiding premature calcification, SVD and reoperation [29]. All biological tissue 255 
valves including the SOLO primarily undergo chemical fixation with GA to provide mechanical 256 
stability, at the expense of susceptibility to calcification. In a unique treatment, Sorin uses HCA  257 
featuring strong electronegative sulfonic groups as post-fixation treatment bonding to neutralize free 258 
toxic aldehyde groups in the SOLO valve [30]. In a subcutaneous rat model, GA-HCA-treated bovine 259 
pericardium showed less calcification than GA alone after explantation (14-84 days) [30]. The 260 
effectiveness, however, has been questioned because this model ignores mechanical and dynamic 261 
stress or blood-surface contact [31]. In fact, results from the subcutaneous rat model were the exact 262 
opposite of those from the blood contact and the pulsatile models, emphasizing the necessity of blood 263 
contact in preclinical valve testing [31]. Furthermore, and perhaps even more important, stentless 264 
valve implantation techniques are generally more demanding, less reproducible and standardized, and 265 
more dependent on the surgeon’s skill and experience. Importantly, the ideal concept of a stentless 266 
valve prosthesis assumes that it can replace and imitate a native valve, thus adopting nearly identical 267 
functional durability. However, this theoretical idea ignores that the stentless valve may not seat 268 
adequately in the native aortic root. In detail, correct sizing and perfectly symmetrical implantation to 269 
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ensure low leaflet stress is only rarely obtained with heterogeneous strain and elongation, compression, 270 
shear, and torsional deformation for the three sinuses [32], whereas the SOLO is constructed perfectly 271 
symmetrical and thereby causes stress variations on the leaflets [1, 33]. In the sheep model, the left- 272 
and non-coronary sinuses were found to undergo clockwise torsion during the ejection phase, while 273 
the right sinus undergoes counterclockwise torsion [32]. This puts stress on the NCC/RCC 274 
commissure and could explain why tears were predominantly seen close to this particular location. 275 
Any malpositioning and asymmetry between the native anatomy and the stentless tissue valve may 276 
cause small distortions with eccentric regurgitation, increased chronic mechanical stress, potentially 277 
leading to fatigue over time and premature valve deterioration [33]. Given the large individual 278 
variability in root anatomy, particularly of the non-coronary sinus, which is usually larger than left- 279 
and right-coronary sinuses (with a larger volume, increased height, width, leaflet size and thickness) [1, 280 
32], symmetric implantation and tension-free positioning can hardly be guaranteed. As a consequence, 281 
the observation of root anatomy, correct sizing and symmetric implantation of the SOLO must be 282 
given particular attention.  283 
 284 
 285 
Limitation 286 
At the time of introduction of the SOLO stentless prosthesis, no prior experience was available, and 287 
surgeons were engaged in proctoring and teaching, which could have influenced patient selection and 288 
technical precision. This study was neither designed to investigate the cause of SOLO-associated 289 
postoperative thrombocytopenia, nor the structural cardiac changes, i.e. the mass regression and its 290 
influence on survival. With regard to long-term adverse events, not all causes of death could be 291 
clarified. However, it must be expected that SVD in some patients contributed to premature death, 292 
particularly because 2/3 of patients diagnosed with SVD did not undergo re-operation for various 293 
reasons, and concomitant procedures do not fully explain the difference in mortality between isolated 294 
and combined procedures. Thus, competing events may potentially have  influenced the assessment of 295 
other aortic-valve related adverse events. Alternatively, we combined all endpoints to evaluate overall 296 
successful AVR with the SOLO stentless prosthesis; albeit at the cost of losing clinically relevant 297 
information. Because our data reports outcomes from a single institution, we caution a premature final 298 
conclusion regarding the SOLO; additional data from other centers are warranted to help to determine 299 
long-term durability of the SOLO prosthesis.  300 
 301 
In conclusion, the SOLO stentless valve is safe to implant, shows excellent hemodynamic 302 
performance as well as early- and mid-term results. There were 26 cases of SVD during the follow-up 303 
period. Multivariate Cox regression analysis identified only younger age as an independent predictor 304 
for SVD, but not renal dysfunction, diabetes, arterial hypertension, nor PPM as continuous variable. 305 
However, actuarial freedom from SVD and explantation decreased markedly after only 5 ̶ 6 years and 306 
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was only 70% and 82% at 9 years, implying that the SOLO durability is lower than that of 307 
conventional stented prostheses in our institution. 308 
 309 
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Table 1: Patient preoperative characteristics 
 
 
 
 
BMI=body mass index, BSA=body surface area, COPD=chronic obstructive pulmonary disease,   
LVEF=left ventricular ejection fraction, NHYA=New York Heart Association, Data as mean ± SD 
 
  
Number of patients 149 
Age (y) 73.6 ± 8.7 (46.1-87.4) 
Gender  
  Male (n, %) 81 (54.4) 
  Female (n, %) 68 (45.6) 
BMI (kg/m2) 27.0 ± 5.9 (16.9-29.4) 
BSA (Dubois) m2 1.82 ± 0.29 (1.27-2.20) 
Diabetes mellitus (n, %)  34 (22.8) 
Arterial hypertension (n, %) 130 (87.2) 
Renal impairment (n, %)   24 (16.1) 
Peripheral artery disease (n, %)   62 (14.1) 
Carotid stenosis (n, %)   14 (10.1) 
COPD (n, %)   25 (9.4) 
LVEF (%) 55.4 ± 12.3 
History of cerebral events (n, %) 17 (11.4) 
NYHA class  
   NYHA I  14 (9.4) 
   NYHA II    62 (41.6) 
   NYHA III  54 (36.2) 
   NYHA IV    19 (12.8) 
Valve pathology  
   Stenosis 126 (84.6) 
   Regurgitation   10 (6.7) 
   Combined   13 (8.7) 
Preoperative rhythm  
 Sinus Data as mean ± SD 120 (80.5) 
 Chronic atrial fibrillation  21 (14.1) 
 Heart block  2 (1.3) 
 Paced 6 (4.0) 
EuroScore II, total 5.70 ± 8.88 
   EuroScore II, isolated AVR 2.69 ± 3.36 
   EuroScore II, combined procedures 8.67 ± 11.34 
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Table 2:  Operative data 
 
 
*one or more concomitant procedures, AVR=aortic valve replacement, MVR=mitral valve 
repair/replacement, CABG=coronary artery bypass grafting, TVR=tricuspid valve repair 
(tricuspid annuloplasty), DVR=double valve replacement, PFO=persistent foramen ovale, 
CPB=cardiopulmonary bypass, RBC=red blood cells, a 51.1% of patients received one or 
more RBC units, b 14.4% of patients received one or more platelet units, values are n (%) 
 
  
Procedures 149 
   Isolated AVR 75 
   Combined procedures* 74 
      CABG, n 59  
      Grafts, n 1.9 ± 1.0 
      CABG+MVR, n 5  
      CABG+TVR, n 1  
      MVR (DVR), n 1  
      MVR (DVR)+TVR, n 1  
      Tricuspid annuloplasty, n 1  
      Ascendens tube graft, n 3  
      Ablation, n 2  
      PFO-closure, n 8  
      Other, n 4  
Labeled valve size  
   #19  3 (2.0) 
   #21  28 (18.8) 
   #23  44 (29.5) 
   #25  39 (26.2) 
   #27 35 (23.5) 
CPB time (min)  
   Isolated procedures 64 ± 14 
   Combined procedures 95 ± 31 
Cross-clamp time (min)    
   Isolated procedures   47 ± 13 
   Combined procedures   71 ± 23 
RBC unitsa    
   Isolated procedures   2.4 ± 1.3 
   Combined procedures   3.2 ± 2.1 
plateletsb    
   Isolated procedures   1.5 ± 0.9 
   Combined procedures   1.8 ± 1.1 
30-day mortality  
   Isolated  procedures   1/75 (1.3) 
   Combined procedures   3/74 (4.0) 
   Overall 4/149 (2.7) 
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Table 3:  Estimates on freedom from major adverse events 
SVD = structural valve deterioration 
estimate year 1 year 2 year 3 year 4 year 5 year 6 year 7 year 8 year 9 year 10 
freedom from           
death 0.94 [0.89‒0.97] 0.91 [0.85‒0.94] 0.86 [0.80‒0.91] 0.80 [0.73‒0.86] 0.75 [0.67‒0.81] 0.69 [0.61‒0.76] 0.66 [0.57‒0.73] 0.59 [0.50‒0.68] 0.57 [0.47‒0.66] 0.57 [0.47‒0.66] 
SVD 1.00 [1.00‒1.00] 0.99 [0.94‒1.00] 0.99 [0.94‒1.00] 0.97 [0.92‒0.99] 0.92 [0.86‒0.96] 0.88 [0.81‒0.93] 0.81 [0.72‒0.88] 0.73 [0.62‒0.81] 0.70 [0.57‒0.79] 0.60 [0.37‒0.77] 
explantation 0.99 [0.95‒1.00] 0.96 [0.92‒0.99] 0.96 [0.92‒0.99] 0.96 [0.91‒0.98] 0.95 [0.89‒0.97] 0.95 [0.89‒0.97] 0.92 [0.86‒0.96] 0.85 [0.75‒0.92] 0.82 [0.69‒0.90] 0.82 [0.69‒0.90] 
explantation for 
SVD 
1.00 [1.00‒1.00] 0.99 [0.94‒1] 0.99 [0.94‒1.00] 0.99 [0.94‒1.00] 0.98 [0.93‒0.99] 0.98 [0.93‒0.99] 0.95 [0.88‒0.98] 0.88 [0.77‒0.94] 0.84 [0.71‒0.92] 0.84 [0.71‒0.92] 
endocarditis 0.99 [0.95‒1.00] 0.99 [0.95‒1.00] 0.98 [0.93‒0.99] 0.98 [0.93‒0.99] 0.98 [0.93‒0.99] 0.98 [0.93‒0.99] 0.97 [0.93‒0.99] 0.97 [0.91‒0.99] 0.97 [0.91‒0.99] 0.97 [0.91‒0.99] 
thromboembolism 0.99 [0.99 0.93]  0.99 [0.95‒1.00] 0.99 [0.95‒1.00] 0.99 [0.95‒1.00] 0.99 [0.95‒1.00] 0.99 [0.95‒1.00] 0.99 [0.95‒1.00] 0.99 [0.95‒1.00] 0.99 [0.95‒1.00] 0.99 [0.95‒1.00] 
combined overall 
failure 
0.93 [0.87‒0.96] 0.88 [0.82‒0.92] 0.84 [0.77‒0.89] 0.77 [0.69‒0.83] 0.69 [0.61‒0.76] 0.60 [0.52‒0.68] 0.53 [0.45‒0.61] 0.45 [0.36‒0.53] 0.41 [0.31‒0.50] 0.35 [0.22‒0.48] 
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